Mentalization-Based Therapy to Prevent Suicidal Behavior in Adolescents With Bipolar Disorder
| Status: | Completed |
|---|---|
| Conditions: | Psychiatric, Bipolar Disorder |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 13 - 21 |
| Updated: | 4/2/2016 |
| Start Date: | January 2014 |
| End Date: | September 2015 |
| Contact: | David J Miklowitz, Ph.D. |
| Email: | dmiklowitz@mednet.ucla.edu |
| Phone: | 310-267-2659 |
Children and adolescents with early-onset bipolar disorder (BD) are at high risk for
intentionally hurting themselves. Although there are therapies in existence for these youths
with BD, they do not address suicide prevention specifically. Mentalization-based therapy
for adolescents (MBT-A) has been shown to be helpful in reducing self-harm in the adolescent
and adult population with borderline personality disorder. The investigators will modify the
MBT-A treatment procedures for persons with BD who have had a recent period of suicidal
ideation or behavior.
intentionally hurting themselves. Although there are therapies in existence for these youths
with BD, they do not address suicide prevention specifically. Mentalization-based therapy
for adolescents (MBT-A) has been shown to be helpful in reducing self-harm in the adolescent
and adult population with borderline personality disorder. The investigators will modify the
MBT-A treatment procedures for persons with BD who have had a recent period of suicidal
ideation or behavior.
Youth with early-onset bipolar disorder (BD) are at an elevated risk for intentional
self-harm compared to healthy adolescents or adolescents with other psychiatric disorders.
Adolescents vulnerable to emotion dysregulation and self-harm often have deficits in the
ability to mentalize: to understand, acknowledge, and predict thoughts and feelings in
oneself and others. Mentalization-based therapy for adolescents (MBT-A) has been shown to be
more effective than 'usual care' in reducing self-harm for adolescents and adults with
borderline personality disorder. MBT-A includes psychoeducational and coping strategies that
may prove quite effective for bipolar adolescents who are at elevated risk for self-harm.
Participation in this study will last 9 months. All participants will receive a thorough
medical-psychiatric evaluation. All youth will be able to receive pharmacotherapy with a
study psychiatrist in the CHAMP clinic. The MBT-A will consist of up to 21 weekly, biweekly
and monthly individual sessions interspersed with 9 monthly family sessions (30 therapy
hours total). Participants will also complete follow-up assessments every 3 months for 9
months. These assessments will include research interviews and questionnaires.
self-harm compared to healthy adolescents or adolescents with other psychiatric disorders.
Adolescents vulnerable to emotion dysregulation and self-harm often have deficits in the
ability to mentalize: to understand, acknowledge, and predict thoughts and feelings in
oneself and others. Mentalization-based therapy for adolescents (MBT-A) has been shown to be
more effective than 'usual care' in reducing self-harm for adolescents and adults with
borderline personality disorder. MBT-A includes psychoeducational and coping strategies that
may prove quite effective for bipolar adolescents who are at elevated risk for self-harm.
Participation in this study will last 9 months. All participants will receive a thorough
medical-psychiatric evaluation. All youth will be able to receive pharmacotherapy with a
study psychiatrist in the CHAMP clinic. The MBT-A will consist of up to 21 weekly, biweekly
and monthly individual sessions interspersed with 9 monthly family sessions (30 therapy
hours total). Participants will also complete follow-up assessments every 3 months for 9
months. These assessments will include research interviews and questionnaires.
Inclusion Criteria:
- Diagnosis of Bipolar Disorder I, Bipolar Disorder II, or Bipolar Disorder Not
Otherwise Specified
- Living with or in close contact with at least one parent who is willing to
participate
- Have had at least 1 week in the prior 3 months of significant suicidal ideation
and/or at least one suicidal event in the 3 months prior to study intake.
- Willing to be treated pharmacologically by a psychiatrist in the UCLA Child and
Adolescent Mood Disorders (CHAMP) clinic
Exclusion Criteria:
- Participants requiring immediate hospitalization
- Diagnosis of borderline personality disorder, schizophrenia, or schizoaffective
disorder.
- Current substance dependence disorder
We found this trial at
1
site
University of California at Los Angeles The University of California, Los Angeles (UCLA) is an...
Click here to add this to my saved trials
